Association of a common genetic variant (insertion/deletion) in ACE gene with prostate cancer susceptibility in a Tunisian population.
Alu repeat sequence
North Africa
Tunisia
angiotensin conversion enzymes
polymorphism
prostate cancer
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
07
11
2021
received:
05
10
2021
accepted:
09
11
2021
pubmed:
21
11
2021
medline:
22
3
2022
entrez:
20
11
2021
Statut:
ppublish
Résumé
Angiotensin-converting enzyme (ACE) plays a pivotal role in several pathologies including cancers. The association of insertion/deletion (I/D) polymorphism of the ACE gene with prostate cancer (PC) risk remains controversial. We aimed to investigate for the first time, to our Knowledge, in North Africa the potential relationship between ACE I/D polymorphism with PC susceptibility and clinical outcomes of PC patients. This case-control study included 143 healthy individuals and 124 patients diagnosed with PC. Using genomic DNA, the samples were genotyped for ACE I/D polymorphism by polymerase chain reaction (PCR). We found that The D allele is significantly associated with an increased risk of PC and D/D + D/I genotypes were at 3 times increased risk of PC ([p = 0.005], OR = 2.95, IC 95% = 1.26-7.09) compared with I/I genotype (p = 0.003, OR = 0.3, IC 95% = 0.12-0.74). We observed an association between D/D and D/I genotypes with advanced age (≥70 years) (p = 0.014; r The ACE I/D polymorphism is likely to predispose to PC and could play a role in PC progression and aggressiveness.
Sections du résumé
BACKGROUND
BACKGROUND
Angiotensin-converting enzyme (ACE) plays a pivotal role in several pathologies including cancers. The association of insertion/deletion (I/D) polymorphism of the ACE gene with prostate cancer (PC) risk remains controversial. We aimed to investigate for the first time, to our Knowledge, in North Africa the potential relationship between ACE I/D polymorphism with PC susceptibility and clinical outcomes of PC patients.
METHODS
METHODS
This case-control study included 143 healthy individuals and 124 patients diagnosed with PC. Using genomic DNA, the samples were genotyped for ACE I/D polymorphism by polymerase chain reaction (PCR).
RESULTS
RESULTS
We found that The D allele is significantly associated with an increased risk of PC and D/D + D/I genotypes were at 3 times increased risk of PC ([p = 0.005], OR = 2.95, IC 95% = 1.26-7.09) compared with I/I genotype (p = 0.003, OR = 0.3, IC 95% = 0.12-0.74). We observed an association between D/D and D/I genotypes with advanced age (≥70 years) (p = 0.014; r
CONCLUSION
CONCLUSIONS
The ACE I/D polymorphism is likely to predispose to PC and could play a role in PC progression and aggressiveness.
Identifiants
pubmed: 34799866
doi: 10.1002/jcla.24129
pmc: PMC8761439
doi:
Substances chimiques
ACE protein, human
EC 3.4.15.1
Peptidyl-Dipeptidase A
EC 3.4.15.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24129Informations de copyright
© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
J Steroid Biochem Mol Biol. 1991;40(4-6):511-5
pubmed: 1958553
Dig Surg. 2011;28(4):258-62
pubmed: 21654174
Gene. 2020 Oct 20;758:144944
pubmed: 32628976
J Pathol. 2004 Mar;202(3):330-5
pubmed: 14991898
Anticancer Res. 2007 Mar-Apr;27(2):933-6
pubmed: 17465223
Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):845-857
pubmed: 29348298
PLoS One. 2019 Dec 26;14(12):e0226553
pubmed: 31877149
Cancer. 2009 Aug 15;115(16):3661-9
pubmed: 19598210
J Cancer Res Ther. 2018 Jun;14(Supplement):S375-S380
pubmed: 29970692
Endocr Connect. 2016 May;5(3):128-35
pubmed: 27068935
Cancer Res. 2003 Oct 15;63(20):6984-7
pubmed: 14583500
Clin Rheumatol. 2018 Dec;37(12):3309-3317
pubmed: 30094750
Med Oncol. 2012 Sep;29(3):1964-71
pubmed: 21874567
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Circ Res. 2018 Dec 7;123(12):1298-1312
pubmed: 30566058
Curr Cancer Drug Targets. 2011 May;11(4):442-50
pubmed: 21395553
J Clin Invest. 1990 Oct;86(4):1343-6
pubmed: 1976655
Trans Am Clin Climatol Assoc. 2017;128:14-23
pubmed: 28790484
Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3225-3231
pubmed: 30486620
Surg Clin North Am. 2015 Oct;95(5):1023-39
pubmed: 26315521
J Clin Endocrinol Metab. 1986 Oct;63(4):1008-15
pubmed: 3528208
J Am Soc Nephrol. 2001 Dec;12(12):2832-2837
pubmed: 11729254
Int J Clin Exp Pathol. 2014 Aug 15;7(9):6291-300
pubmed: 25337282
J Cell Biochem. 2019 Dec;120(12):19388-19395
pubmed: 31478246
Transl Oncol. 2018 Apr;11(2):233-242
pubmed: 29413755
Int J Mol Med. 2017 Nov;40(5):1573-1581
pubmed: 28949385
Hum Genet. 2004 Jul;115(2):91-6
pubmed: 15164285
J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):453-8
pubmed: 25092717
Prostate. 1990;17(4):337-47
pubmed: 2251225
Gan To Kagaku Ryoho. 2009 Aug;36(8):1228-33
pubmed: 19692759
Rev Assoc Med Bras (1992). 2018 Nov;64(11):1017-1022
pubmed: 30570054
J Renin Angiotensin Aldosterone Syst. 2009 Dec;10(4):241-6
pubmed: 20026870
Cancer Causes Control. 2010 Feb;21(2):289-300
pubmed: 19902366
BMC Cancer. 2021 Feb 12;21(1):158
pubmed: 33579229
Adv Clin Exp Med. 2020 May;29(5):581-585
pubmed: 32442362
J Neural Transm (Vienna). 2016 Mar;123(3):317-21
pubmed: 26456241
Hum Genomics. 2021 Jan 4;15(1):2
pubmed: 33390179
Int J Cancer. 2015 Mar 1;136(5):1104-16
pubmed: 24978482
Oncotarget. 2019 Oct 29;10(59):6349-6361
pubmed: 31695843
J Clin Lab Anal. 2022 Jan;36(1):e24129
pubmed: 34799866
J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482
pubmed: 29598869
J Int Med Res. 2019 Dec;47(12):5917-5925
pubmed: 31694436
J Renin Angiotensin Aldosterone Syst. 2015 Sep;16(3):695-9
pubmed: 25208933
Gene. 2018 Jan 10;639:62-68
pubmed: 29017962
Cancer. 2008 Feb 15;112(4):748-57
pubmed: 18181094
Mol Carcinog. 2010 Dec;49(12):1022-30
pubmed: 20945417
Carcinogenesis. 2012 Jul;33(7):1259-69
pubmed: 22523086
Prostate Cancer Prostatic Dis. 2005;8(1):95-102
pubmed: 15711606
Med Sci Monit. 2016 Nov 01;22:4132-4138
pubmed: 27801393
J Renin Angiotensin Aldosterone Syst. 2013 Mar;14(1):74-81
pubmed: 22679277
Peptides. 2012 Oct;37(2):200-6
pubmed: 22884921
J Renin Angiotensin Aldosterone Syst. 2019 Oct-Dec;20(4):1470320319881932
pubmed: 31642377
Ann Epidemiol. 2001 Nov;11(8):534-42
pubmed: 11709272
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Prostate Cancer. 2020 Feb 7;2020:5959134
pubmed: 32089890
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
DNA Cell Biol. 2013 May;32(5):268-73
pubmed: 23570557
Curr Vasc Pharmacol. 2004 Oct;2(4):385-99
pubmed: 15320819
Am J Hum Genet. 2001 May;68(5):1139-48
pubmed: 11283791